• Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 422.57%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.11
▼ -0.33 (-13.55%)

This chart shows the closing price for BCAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioAtla Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCAB

Analyst Price Target is $11.00
▲ +422.57% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for BioAtla in the last 3 months. The average price target is $11.00, with a high forecast of $14.00 and a low forecast of $7.00. The average price target represents a 422.57% upside from the last price of $2.11.

This chart shows the closing price for BCAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in BioAtla. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$12.00N/A
3/27/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $7.00Low
12/5/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$12.00Low
11/7/2023HC WainwrightLower TargetBuy ➝ Buy$17.00 ➝ $10.00Low
9/25/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$17.00 ➝ $14.00Low
8/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$17.00Low
8/2/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$12.00Low
8/2/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$19.00 ➝ $17.00N/A
4/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$25.00Low
4/3/2023JPMorgan Chase & Co.Lower TargetOverweight$23.00 ➝ $19.00Low
3/28/2023BTIG ResearchLower TargetBuy$13.00Low
3/27/2023JMP SecuritiesLower Target$17.00 ➝ $12.00Low
3/24/2023EF Hutton Acquisition Co. IReiterated RatingBuy$25.00Low
3/24/2023HC WainwrightLower TargetBuy$20.00 ➝ $17.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$25.00Low
11/4/2022Credit Suisse GroupBoost TargetNeutral$4.00 ➝ $8.00Low
9/15/2022JMP SecuritiesInitiated CoverageOutperform$17.00Low
8/10/2022HC WainwrightLower TargetBuy$25.00 ➝ $20.00Low
5/5/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$35.00 ➝ $5.00High
3/21/2022HC WainwrightInitiated CoverageBuy$25.00High
6/28/2021Roth CapitalInitiated CoverageBuy$75.00Medium
5/4/2021JPMorgan Chase & Co.Boost TargetOverweight$45.00 ➝ $64.00High
3/26/2021BTIG ResearchBoost TargetBuy$47.00 ➝ $87.00Medium
1/11/2021Credit Suisse GroupInitiated CoverageOutperform$49.00High
1/11/2021Jefferies Financial GroupInitiated CoverageBuy$51.00High
1/11/2021JPMorgan Chase & Co.Initiated CoverageOverweight$45.00High
1/11/2021BTIG ResearchInitiated CoverageBuy$47.00High
(Data available from 4/21/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2023
  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/23/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2024

Current Sentiment

  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
BioAtla logo
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.11
Low: $2.10
High: $2.51

50 Day Range

MA: $2.81
Low: $2.11
High: $3.92

52 Week Range

Now: $2.11
Low: $1.24
High: $4.07

Volume

796,590 shs

Average Volume

756,835 shs

Market Capitalization

$101.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of BioAtla?

The following equities research analysts have issued stock ratings on BioAtla in the last twelve months: HC Wainwright, JMP Securities, and JPMorgan Chase & Co..
View the latest analyst ratings for BCAB.

What is the current price target for BioAtla?

3 Wall Street analysts have set twelve-month price targets for BioAtla in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 422.6%. JPMorgan Chase & Co. has the highest price target set, predicting BCAB will reach $14.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for BioAtla in the next year.
View the latest price targets for BCAB.

What is the current consensus analyst rating for BioAtla?

BioAtla currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCAB will outperform the market and that investors should add to their positions of BioAtla.
View the latest ratings for BCAB.

What other companies compete with BioAtla?

How do I contact BioAtla's investor relations team?

The company's listed phone number is 858-558-0708 and its investor relations email address is [email protected]. The official website for BioAtla is www.bioatla.com. Learn More about contacing BioAtla investor relations.